Allogene Therapeutics Ownership | Who Owns Allogene Therapeutics?


OverviewForecastFinancialsChartTranscripts

Allogene Therapeutics Ownership Summary


Allogene Therapeutics is owned by 44.72% institutional investors, 16.63% insiders, and 38.65% retail investors. Pfizer is the largest institutional shareholder, holding 9.92% of ALLO shares. American Funds SMALLCAP World A is the top mutual fund, with 5.10% of its assets in Allogene Therapeutics shares.

ALLO Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockAllogene Therapeutics44.72%16.63%38.65%
SectorHealthcare Stocks 231.98%10.74%-142.72%
IndustryBiotech Stocks 381.47%10.55%-292.02%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Pfizer22.03M9.92%$30.18M
Blackrock16.45M9.72%$38.32M
Tpg gp a18.72M8.55%$23.21M
Blackrock funding, inc. /de17.68M7.96%$24.22M
Vanguard group9.25M4.17%$12.67M
Primecap management co/ca/8.14M3.67%$11.15M
Patient square capital lp4.96M2.24%$6.80M
Woodline partners lp4.36M1.99%$5.41M
Geode capital management3.93M1.77%$5.39M
Frazier life sciences management3.87M1.77%$4.80M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Pfizer22.03M12.76%$30.18M
Vida ventures advisors1.80M7.59%$2.23M
Wildcat capital management2.92M2.93%$4.00M
Patient square capital lp4.96M1.46%$6.80M
Tpg gp a18.72M1.26%$23.21M
Dafna capital management1.38M0.42%$1.71M
Frazier life sciences management3.87M0.14%$4.80M
Lynx1 capital management lp546.12K0.14%$677.19K
Harold davidson & associates194.75K0.12%$266.81K
Moloney securities asset management514.00K0.08%$637.36K

Top Buyers

HolderShares% AssetsChange
Blackrock16.45M0.00%6.79M
Patient square capital lp4.96M1.46%1.98M
Two sigma investments, lp3.38M0.01%1.77M
Goldman sachs group2.29M0.00%1.09M
Primecap management co/ca/8.14M0.01%1.06M

Top Sellers

HolderShares% AssetsChange
Capital world investors---11.15M
Lynx1 capital management lp546.12K0.14%-10.51M
Darwin global management---10.48M
Boxer capital---3.85M
Foresite capital management vi---2.88M

New Positions

HolderShares% AssetsChangeValue
Jacobs levy equity management878.96K0.01%878.96K$2.05M
Bridgeway capital management250.00K0.01%250.00K$310.00K
Headlands139.96K0.01%139.96K$173.55K
Cubist systematic strategies102.77K0.00%102.77K$127.44K
Atom investors lp85.93K0.01%85.93K$106.55K

Sold Out

HolderChange
Capital performance advisors llp-41.00
Raymond james financial-45.00
Dunhill financial-70.00
Pnc financial services group-85.00
Federation des caisses desjardins du quebec-100.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025108-37.93%99,292,779-38.89%440.81%46-51.06%31-16.22%
Sep 30, 20251668.50%162,395,329-2.90%741.27%8526.87%37-11.90%
Jun 30, 2025160-6.98%183,929,908-6.69%841.00%66-27.47%4714.63%
Mar 31, 2025170-1.73%196,870,7584.48%911.13%90-2.17%41-
Dec 31, 20241655.10%185,488,00512.84%881.44%8927.14%40-11.11%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
American Funds SMALLCAP World A11.15M5.10%-1.12M
Vanguard Capital Opportunity Inv5.19M2.31%768.93K
Fidelity Growth Compy Commingled Pl O4.58M2.19%-
Vanguard Total Stock Mkt Idx Inv4.88M2.17%-
Vanguard US Total Market Shares ETF4.34M2.00%-
Fidelity Select Health Care4.00M1.88%-350.00K
SPDR® S&P Biotech ETF3.90M1.84%-23.78K
Fidelity Series Small Cap Opps3.54M1.69%-141.30K
iShares Russell 2000 ETF3.74M1.67%2.02M
PRIMECAP Odyssey Aggressive Growth2.73M1.21%264.05K

Recent Insider Transactions


DateNameRoleActivityValue
Mar 02, 2026Beneski Benjamin Machinas SVP, Chief Technical OfficerSell$18.54K
Feb 02, 2026Beneski Benjamin Machinas SVP, Chief Technical OfficerSell$13.06K
Feb 02, 2026Chang David D President and CEOSell$171.48K
Feb 02, 2026Parker Geoffrey M. CHIEF FINANCIAL OFFICERSell$42.24K
Feb 02, 2026Douglas Earl Martin SVP, General CounselSell$40.30K

Insider Transactions Trends


DateBuySell
2026 Q1-8
2025 Q4-2
2025 Q2-2
2025 Q1-9
2024 Q4-2

ALLO Ownership FAQ


Who Owns Allogene Therapeutics?

Allogene Therapeutics shareholders are primarily institutional investors at 44.72%, followed by 16.63% insiders and 38.65% retail investors. The average institutional ownership in Allogene Therapeutics's industry, Biotech Stocks , is 381.47%, which Allogene Therapeutics falls below.

Who owns the most shares of Allogene Therapeutics?

Allogene Therapeutics’s largest shareholders are Pfizer (22.03M shares, 9.92%), Blackrock (16.45M shares, 9.72%), and Tpg gp a (18.72M shares, 8.55%). Together, they hold 28.20% of Allogene Therapeutics’s total shares outstanding.

Does Blackrock own Allogene Therapeutics?

Yes, BlackRock owns 9.72% of Allogene Therapeutics, totaling 16.45M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 38.32M$. In the last quarter, BlackRock increased its holdings by 6.79M shares, a 70.37% change.

Who is Allogene Therapeutics’s biggest shareholder by percentage of total assets invested?

Pfizer is Allogene Therapeutics’s biggest shareholder by percentage of total assets invested, with 12.76% of its assets in 22.03M Allogene Therapeutics shares, valued at 30.18M$.

Who is the top mutual fund holder of Allogene Therapeutics shares?

American Funds SMALLCAP World A is the top mutual fund holder of Allogene Therapeutics shares, with 5.10% of its total shares outstanding invested in 11.15M Allogene Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools